Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280769 | 0.79 | CNR2 (0.36) | PTGDR2HTR6PIK3CDPIK3R2PIK3CA | |
| SCHEMBL15049938 | 0.79 | PIK3CD (0.41) | HTR6PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL660444 | 0.79 | PIK3CD (0.41) | HTR6PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL657902 | 0.79 | PIK3CD (0.41) | HTR6PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL19221842 | 0.78 | HTR6 (0.38) | HTR6PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL661574 | 0.77 | CCNK (0.39) | HTR6PIK3CA | |
| SCHEMBL111185 | 0.76 | PIK3CD (0.45) | HTR6PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL109125 | 0.75 | KMT2A (0.36) | PTGDR2HTR6PIK3CDPIK3CAPIK3CB | |
| SCHEMBL27933961 | 0.75 | HTR6 (0.36) | PTGDR2HTR6 | |
| SCHEMBL110755 | 0.75 | HTR6 (0.39) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586590-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-19 | — | — | US | disclosed |
| US-20130131080-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131080-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PTGDR2 2486/4885HTR6 4373/4885PIK3CD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.